Sana Biotechnology (Sana Biotechnology) EPS (Diluted) : $-1.47 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology EPS (Diluted)?

Sana Biotechnology's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.45. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

Sana Biotechnology's EPS (Basic) for the three months ended in Dec. 2023 was $-0.45. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

Sana Biotechnology's EPS without NRI for the three months ended in Dec. 2023 was $-0.45. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

During the past 3 years, the average EPS without NRIGrowth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Sana Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 3.50% per year. The lowest was -12.50% per year. And the median was -4.50% per year.

Sana Biotechnology EPS (Diluted) Historical Data

The historical data trend for Sana Biotechnology's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology EPS (Diluted) Chart

Sana Biotechnology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.00

-1.63

-2.14

-1.43

-1.46

Sana Biotechnology Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial														-0.42	-0.43	-0.59	-	-0.45

Competitive Comparison of Sana Biotechnology's EPS (Diluted)

For the Biotechnology subindustry, Sana Biotechnology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sana Biotechnology's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's PE Ratio falls into.

Sana Biotechnology EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sana Biotechnology's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-283.255	-	0)	/	194.541
	=	-1.46

Sana Biotechnology's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-88.117	-	0)	/	197.349
	=	-0.45

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47

Sana Biotechnology (NAS:SANA) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sana Biotechnology EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sana Biotechnology (Sana Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102

Website

https://www.sana.com

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.

Executives

Christian Hordo	officer: SVP, Chief Business Officer	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams	officer: EVP & President, R&D	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy	officer: EVP & General Counsel	C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang	director	C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald	officer: See Remarks	C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal	officer: See Remarks	60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631